Last reviewed 2026-04-19 · How we verify

Hsp90 Inhibitor AUY 922

SCRI Development Innovations, LLC · Phase 1 active Small molecule

Hsp90 Inhibitor AUY 922 is a Small molecule drug developed by SCRI Development Innovations, LLC. It is currently in Phase 1 development.

At a glance

Generic name	Hsp90 Inhibitor AUY 922
Sponsor	SCRI Development Innovations, LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Hsp90 Inhibitor AUY 922 CI brief — competitive landscape report
Hsp90 Inhibitor AUY 922 updates RSS · CI watch RSS
SCRI Development Innovations, LLC portfolio CI

Frequently asked questions about Hsp90 Inhibitor AUY 922

What is Hsp90 Inhibitor AUY 922?

Hsp90 Inhibitor AUY 922 is a Small molecule drug developed by SCRI Development Innovations, LLC.

Who makes Hsp90 Inhibitor AUY 922?

Hsp90 Inhibitor AUY 922 is developed by SCRI Development Innovations, LLC (see full SCRI Development Innovations, LLC pipeline at /company/scri-development-innovations-llc).

What development phase is Hsp90 Inhibitor AUY 922 in?

Hsp90 Inhibitor AUY 922 is in Phase 1.

Manufacturer: SCRI Development Innovations, LLC — full pipeline
Compare: Hsp90 Inhibitor AUY 922 vs similar drugs
Pricing: Hsp90 Inhibitor AUY 922 cost, discount & access